Moxifloxacin Tablets 400mg

Name: Moxifloxacin Tablets 400mg
Brand: Artemisine Medicines Technology Co., Ltd.

Tablets

Moxifloxacin 400mg tablets — a broad-spectrum fluoroquinolone antibiotic for respiratory tract, skin and intra-abdominal infections; also WHO-recommended as a Group A fluoroquinolone in MDR-TB treatment regimens. GMP manufactured by Artemisine Medicines Technology with full documentation (COA, COPP, DMF, CTD dossiers) for global export.

Product Name	Moxifloxacin Tablets 400mg
Dosage Form	Tablets
Strength	400 mg
Standards	BP / ENTERPRISE
Packing	10×2 blister (20 tablets per box)
Documents	COA, COPP, DMF, CTD Dossiers
MOQ	Contact us for MOQ and current stock

Request Quotation › ← Back to Tablets

WHO Prescribing Guidance

Indications · Administration · Dosage · Precautions

Reference information summarised from WHO prescribing guidance. Expand each item below — clinical use must always follow the locally approved product insert.

🎯Indications▾

Community-acquired pneumonia, acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, uncomplicated skin and skin-structure infections, complicated intra-abdominal infections. Per WHO consolidated guidelines on drug-resistant tuberculosis, moxifloxacin is a Group A fluoroquinolone component of MDR/RR-TB treatment regimens.

💧Administration▾

Oral, once daily, with or without food. Avoid co-administration with antacids, sucralfate, iron or zinc supplements (chelation reduces absorption — separate by at least 4 hours before or 8 hours after). Pharmacist: dispense the Medication Guide to each patient.

⚖️Dosage▾

Adults: 400 mg once daily. Duration by indication — acute bacterial exacerbation of chronic bronchitis 5 days; community-acquired pneumonia 7–14 days; acute bacterial sinusitis 10 days; skin infections 7 days; intra-abdominal infections 5–14 days.

⚠️Precautions & Warnings▾

Fluoroquinolone class warnings: risk of tendonitis/tendon rupture (elderly, corticosteroid users), peripheral neuropathy and CNS adverse effects — discontinue at first sign. QT prolongation: avoid in known QT prolongation, uncorrected hypokalemia, and with Class Ia or Class III antiarrhythmics. Reserve fluoroquinolones for patients without alternative treatment options for uncomplicated infections. Not recommended in children, adolescents under 18, pregnancy or lactation.

Reference: WHO Model Formulary / WHO Model List of Essential Medicines. For professional reference only — clinical use must follow the locally approved product insert and national treatment guidelines.

Why Order From Us

Factory Direct. Fully Documented.

🛡️

GMP Quality

Full batch testing and quality traceability under standard GMP workshops.

🚢

Fast Delivery

Sufficient stock on regular items, familiar with export logistics to 50+ countries.

📑

Registration Support

COA, DMF, dossier and legalization documents for your market registration.

FAQ

Moxifloxacin Tablets 400mg — Frequently Asked Questions

Which documents are provided for Moxifloxacin Tablets 400mg registration?

Every batch of Moxifloxacin Tablets 400mg ships with a Certificate of Analysis (COA). For market registration we provide COPP, DMF and CTD-format dossiers, plus legalisation support where your authority requires it.

What is the MOQ and lead time for Moxifloxacin Tablets 400mg?

MOQ and lead time for Moxifloxacin Tablets 400mg depend on strength, packaging and destination market. Send us your target market and annual volume — our export team confirms current stock, MOQ and lead time within 24 hours.

Do you support OEM / private label?

Yes. We offer OEM packaging and private-label production for Moxifloxacin Tablets 400mg, subject to the regulatory requirements of the destination market.

Which markets have you exported tablets products to?

We have supplied tablets products to 50+ countries across Africa, Southeast Asia, Latin America and the Middle East, with experience in ministry-of-health registration and international tenders.

How is the quality of Moxifloxacin Tablets 400mg controlled?

Moxifloxacin Tablets 400mg is produced in China-GMP workshops (site re-inspected and passed in 2026), released only after full QC testing against BP / enterprise standards, with retained samples kept for one year beyond the product's expiry date.

Ask About This Product ›